Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9692290 | 0.73 | NPC1 (0.50) | MAOBNR4A1NR4A2NR4A3ALOX5 | |
| SCHEMBL5338612 | 0.72 | MAOB (0.49) | L3MBTL1MAOBNR4A1NR4A2NR4A3 | |
| Benzylphenylether SCHEMBL15539953 | 0.69 | FFAR1 (0.64) | L3MBTL1MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL14347696 | 0.69 | MAOB (0.59) | L3MBTL1MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL339813 | 0.68 | LMNA (0.82) | L3MBTL1MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL27367676 | 0.68 | LMNA (0.82) | L3MBTL1MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL14347698 | 0.68 | NR4A1 (0.57) | MAOBNR4A1NR4A2NR4A3ALOX5 | |
| SCHEMBL30988239 | 0.68 | LMNA (0.58) | L3MBTL1MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL25315317 | 0.68 | NR4A1 (0.53) | MAOBNR4A1NR4A2NR4A3ALOX5 | |
| SCHEMBL102983 | 0.67 | RAB9A (0.83) | L3MBTL1MAOBNR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223881-B2 | Process for the preparation of new antidiabetic agents | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-05-29 | — | — | US | disclosed |
| US-20050096331-A1 | Novel compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES INC. | 2005-05-05 | — | — | US | disclosed |
| US-20030125553-A1 | Process for the preparation of new antidiabetic agents | DR. REDDY'S LABORATORIES LIMITED | 2003-07-03 | — | — | US | disclosed |
| WO-2003053974-A1 | NOVEL COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-07-03 | — | — | WO | disclosed |
| US-6531596-B1 | S(-)-2-methoxy-3-(4-(2-(phenoxazin-10-yl)methoxy) phenyl)propionic acid; benzylating p-hydroxybenzaldehyde or tyrosine; reaction with phenoxazinyl mesylate | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-03-11 | — | — | US | disclosed |
| EP-1124808-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF NEW ANTIDIABETIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026200-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF NEW ANTIDIABETIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125553-A1 | Process for the preparation of new antidiabetic agents | GLP1R, GPR119, SLC5A1 | L3MBTL1 4718/4885MAOB 2027/4885NR4A1 488/4885 |
| US-20050096331-A1 | Novel compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them | GPR119, LIPA, CETP | L3MBTL1 4721/4885MAOB 2637/4885NR4A1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.